X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

By Nicole Longo  |    October 20, 2017
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have...   Read More

How much are hospitals marking up the price of medicines? The answer may surprise you.

By Robert Zirkelbach  |    October 17, 2017
Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of...   Read More

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

By Nicole Longo  |    July 13, 2017
This week, Berkeley Research Group (BRG) released a new whitepaper pushing back on the highly misleading claim that 340B sales are only 2 percent of annual U.S. drug sales. Citing a number of...   Read More

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

By Nicole Longo  |    June 20, 2017
In case you missed it, the Atlanta Journal-Constitution analyzed data on hospital participation in the 340B program in Georgia and found that some hospitals are raking in huge profits – with no...   Read More

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

By Rebecca Davison  |    April 27, 2017
As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...   Read More

340B Spotlight: Audit findings show importance of increased oversight of 340B program

By Rebecca Davison  |    February 9, 2017
The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility,...   Read More

340B Spotlight: Program continues to grow with no end in sight

By Rebecca Davison  |    October 4, 2016
How much is the 340B program growing? Earlier this year, Drug Channels published new 340B purchase data from Apexus, the 340B program’s Prime Vendor.  Apexus’s data show $12 billion of drug sales...   Read More

340B Spotlight: Trends in shifting site of care

By Rachel Licata  |    September 21, 2016
Research has shown once health care services shift from a provider’s office to a hospital, treatment costs for payers and patients increase. One way hospitals drive this site of care shift is...   Read More

340B Spotlight: Retail pharmacies continue to expand the 340B program

By Rebecca Davison  |    August 17, 2016
One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels  found more than one-in-four retail, mail and specialty pharmacies in...   Read More

340B Spotlight: New report raises questions about eligibility metric for 340B hospitals

By Karyn Schwartz  |    August 11, 2016
A new report from the Government Accountability Office (GAO) on how hospitals qualify for certain uncompensated care payments raises questions about how a similar eligibility metric is used to...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates